ArticleCureus2026
Linear IgA Bullous Dermatosis: A Rare Immune-Related Cutaneous Adverse Event Due to Pembrolizumab.
Article in Cureus, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Programmed death-1 inhibitor therapy has emerged as a novel modality for various conditions, including solid organ tumors, autoimmune conditions, and other malignancies. The spectrum of their adverse effects continues to evolve as their use expands across different patient populations and for other diseases. Linear IgA bullous dermatosis has not been described as a typical autoimmune bullous condition associated with pembrolizumab therapy. In this study, we describe a rare cutaneous adverse event associated with pembrolizumab therapy. The patient had been receiving pembrolizumab therapy for advanced lung adenocarcinoma for several years. Few cases of linear IgA bullous dermatosis have been documented in association with immune checkpoint inhibitor-related cutaneous adverse events.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.